Wegovy (Semaglutide)
Home > Blog
Wegovy is approved for weight loss whereas Ozempic is approved for Type 2 diabetes. Generic name for Wegovy and Ozempic is semaglutide.
Novo Nordisk, the manufacturers of Ozempic created a new medicine Wegovy which uses the base molecule semaglutide for weight loss. In 2021, this revolutionary medication gained FDA approval for weight loss and has since helped thousands of people lose weight.
The U.S. Food and Drug Administration (FDA) approved in June 2021 the use of semaglutide for weight loss with the name Wegovy.
Are Ozempic and Wegovy the same medications -Semaglutide?
Novo Nordisk developed Wegovy based on a molecule “semaglutide.” They discovered that for patients who struggle with weight or patients with type 2 diabetes, these medicines curbed their appetites and led to remarkable weight loss. As a result, Novo decided to launch the molecule in a higher dosage under a new brand name Wegovy. Wegovy is the same medication as ozempic.
Wegovy is approved for weight loss whereas Ozempic is approved for Type 2 diabetes. Generic name for Wegovy and Ozempic is semaglutide.
Do you get the same result from ozempic and wegovy ?
Yes, you get the exact same result from Ozempic or Wegovy. People lose an average of 1-3 pounds weight loss a week in these medications. Due to shortages of Wegovy, your provider may choose to prescribe Ozempic for weight-loss at a potentially higher dosage to almost exactly match the weight-loss properties of Wegovy.
It is especially possible when taking compounded medication semaglutide. It has the flexibility of taking the dose your body needs to lose or maintain your goal weight.
How long has the GLP-1 receptor been in the market?
The first GLP-1 receptor agonist (GLP-1 RA) was exenatide, which was approved by the US Food and Drug Administration (FDA) in April 2005 for the treatment of Type 2 diabetes mellitus. GLP-1 receptor medications that are available in the market work in similar mechanisms and help with diabetes and weight loss.
- Exenatide (Byetta) – twice daily injection
- Exenatide extended release (Bydureon bcise) – weekly injection
- Victoza ( Liraglutide) – approved for type 2 diabetes
- Mounjaro approved in May 2022 for Type 2 Diabetes
- Semaglutide (Ozempic) approved in 2017 for type 2 diabetes
- Dulaglutide (Trulicity)- weekly injection approved in 2015 for Type 2 diabetes
- Wegovy approved in 2021 for weight loss
- Semaglutide (Rybelsus) (taken by mouth once daily)
- Saxenda ( Liraglutide) -daily injection- approved for weight loss
- Zepbound approved November 2023 for weight loss
FDA approved medications for weight loss
- Saxenda ( Liraglutide) daily injection approved for weight loss
- Wegovy ( Semaglutide) weekly injection approved in 2021 for weight loss
- Zepbound ( Tirzepatide) weekly injection approved November 2023 for weight loss